本文来自信达证券研发中心2025年3月31日发布的《国药控股(1099.HK)点评报告:减值因素致24年利润短期承压,“稳中求进”经营策略或可修复25年业绩》,欲了解具体内容,请阅读报告原文,唐爱金S1500523080002、章钟涛S1500524030003。事件:公司发布2024年年度业绩公告,2024公司实现营业收入5845.08亿元(yoy-2.02%),归母净利润70.5亿元(yoy-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.